Third Rock Ventures
高管
查看带有其 35 名主要高管的组织结构图
Third Rock Ventures 搜索最多的简介
- Abbie Celniker, Partner, Formation, Development and Strategy
- Neil Exter, Partner, Formation, Development and Strategy
- Chris Robinson, Chief Talent Officer
创建提醒
跟踪 Third Rock Ventures 的高管变动
基金
Third Rock Ventures 拥有 1,523 家竞争者，其中包括 BlackRock (美国(美洲))、Blackstone Group (美国(美洲)) 和 Vanguard (美国(美洲))。
Popular M&A news in 基金
- RIV Capital and Cansortium have announced they will merge (公布2024十月14号)..
- Janus Henderson Group 已收购 Victory Park Capital (公布2024十月7号).
- General Atlantic 已收购 Actis (公布2024十月3号).
基金 行业的其他推荐联系人
消息
Third Rock Ventures 的最新新闻稿
- Septerna Prices Upsized Initial Public Offering - Thu, 10/24/2024 - 21:47
- Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round – Seaport Therapeutics
- Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 | Pliant Therapeutics, Inc.
- insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases
- Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs | Pliant Therapeutics, Inc.
- Septerna Presents New Preclinical Data at ASBMR 2024 Highlighting Therapeutic Potential of Oral Small Molecule Parathyroid Hormone 1 Receptor (PTH1R) Agonists for Hypoparathyroidism - Septerna
- Clasp Therapeutics to Present Preclinical Data Evaluating Novel T Cell Engager Targeting p53 Mutant Solid Tumors
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024 | Pliant Therapeutics, Inc.
- Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) | Fulcrum Therapeutics
- Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer | Terremoto
- View more press releases Close
通过电子邮件
